HLA-DR3

From Wikipedia, the free encyclopedia

Illustration of an HLA-DR (Human MHC class II) antigen receptor with bound antigen
major histocompatibility complex, class II, DR3
Haplotypes groups DRA*01:DRB1*0301 DRA*01:DRB1*0302 DRA*01:DRB1*0303 DRA*01:DRB1*0304
Structure (See HLA-DR)
Identifiers
alpha *0101
Symbol(s) HLA-DRA
EBI-HLA DRA*0101
Identifiers
beta 1 *0301 *0301 *0302 *0303 *0304
Symbol(s) HLA-DRB1
EBI-HLA DRB1*0301
EBI-HLA DRB1*0302
EBI-HLA DRB1*0303
EBI-HLA DRB1*0304
EBI-HLA DRB1*0305
Shared data
Locus chr.6 6p21.31

HLA-DR3 is composed to the HLA-DR17 and HLA-DR18 split 'antigens' serotypes.

Contents

[edit] Serology

DR17 and DR3 recognition of some DRB1*03 alleles[1]
DRB1* DR3 DR17 DR18 Sample
allele  %  %  % size (N)
0301 33 64 0 9698
0302 24 3 66 317
0303 40 60 5
0304 60 20 5
0307 >50 1

Some DR3 also react with HLA-DR17 and/or HLA-DR18. The DRB1*0304 primarily reacts with DR3. The serotypes of *0305, *0306, *0308 to *0331 are unknown.

[edit] Disease associations

[edit] By serotype

HLA-DR3 is associated with early-age onset myasthenia gravis, primary sclerosing cholangitis,[2] and opportunistic infections in AIDS[3], but lowered risk for cancers[4].

[edit] By allele

DRB1*0301 (see HLA-DR17)

DRB1*0302 (See HLA-DR18)

DRB1*0304 is associated it graves disease[5]

[edit] By haplotypes

DR3 and/or DQ2 is associated with Moreen's ulceration[6], "bout onset" multiple sclerosis[7], Grave's disease[8] and systemic lupus erythematosus[9]

DR3-DQ2 linkage is associated with coeliac disease, dermatitis herpetiformis, juvenile diabetes. DR3-DR2 is the serological marker for HLA-DQ2.5cis isoform. Although it cannot identify the alpha ".5" chain of HLA DQ, DQA1*0501 gene is almost always found within the DR3-DQ2 haplotype Eurasia (however is older studies DQA1*0505 is commonly confused with DQA1*0501)
PubMed

[edit] Genetic linkage

DR3 is genetically linked to HLA-DR52, DRB3*0202 allele, and HLA-DQ2 (DQ2.5).

[edit] References

  1. ^ derived from IMGT/HLA
  2. ^ Wiencke K, Karlsen TH, Boberg KM, et al (2007). "Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes". Tissue Antigens 69 (2): 161–9. doi:10.1111/j.1399-0039.2006.00738.x. PMID 17257319. 
  3. ^ Pollack MS, Gold J, Metroka CE, Safai B, Dupont B (1984). "HLA-A,B,C and DR antigen frequencies in acquired immunodeficiency syndrome (AIDS) patients with opportunistic infections". Hum. Immunol. 11 (2): 99–103. PMID 6333416. 
  4. ^ Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ (1990). "HLA antigen frequencies in HIV-1-related Kaposi's sarcoma". J. Acquir. Immune Defic. Syndr. 3 Suppl 1: S51–5. PMID 2395088. 
  5. ^ "{{{title}}}" . PMID 10468973. 
  6. ^ Taylor C, Smith S, Morgan C, Stephenson S, Key T, Srinivasan M, Cunningham E, Watson P (2000). "HLA and Mooren's ulceration.". Br J Ophthalmol 84 (1): 72–5. doi:10.1136/bjo.84.1.72. PMID 10611103. 
  7. ^ Weinshenker B, Santrach P, Bissonet A, McDonnell S, Schaid D, Moore S, Rodriguez M (1998). "Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study.". Neurology 51 (3): 742–7. PMID 9748020. 
  8. ^ Ratanachaiyavong S, Lloyd L, Darke C, McGregor A (1993). "MHC-extended haplotypes in families of patients with Graves' disease.". Hum Immunol 36 (2): 99–111. doi:10.1016/0198-8859(93)90112-E. PMID 8096501. 
  9. ^ Tjernström F, Hellmer G, Nived O, Truedsson L, Sturfelt G (1999). "Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus.". Lupus 8 (2): 103–8. doi:10.1191/096120399678847560. PMID 10192503. 
v • d • e
HLA DR serotypes

DR · DR1 · DR2 · DR3 · DR4 · DR5 · DR6 · DR7 · DR8 · DR9 · DR10 · DR11 · DR12 · DR13 · DR14 · DR15 · DR16 · DR17 · DR18 · DR51 · DR52 · DR53